ASCO GU 2026 highlighted major advances across GU cancers, with LIGHTSPARK-022 and LIGHTSPARK-011 positioning belzutifan-based strategies as key emerging standards in kidney cancer. In bladder cancer, ctDNA continues to show promise for systemic monitoring but remains insufficient for assessing local disease, reinforcing the need for multimodal evaluation. Experts also underscore a growing focus on balancing efficacy with quality of life, as seen in adjuvant trials, while emphasizing that many of these data sets may ultimately increase cure rates and reshape treatment selection.
ZUSDURI (Mitomycin) Demonstrates Sustained Efficacy Across EORTC Risk Groups in Recurrent NMIBC
ZUSDURI (mitomycin) delivers durable tumor control in recurrent low‑grade, intermediate‑risk NMIBC, with 79.6% complete responses at three months and 72.2% event-free survival at 24 months. Effective across all EORTC risk groups, it offers a promising option for bladder preservation and long-term disease management.
